Jun 21, 2023
Jared Crapo, Head of Product and Technology at Kalderos, focuses on drug discounts paid by drug manufacturers to pharmacy benefit managers, commercial or government payers, and healthcare providers. Congress created the 340B Drug Discount Program and the Medicaid Drug Rebate Program to support healthcare for underserved patients. While these programs have dramatically grown, so too have the complexities and confusion about discounts and disagreements about payments.
Jared explains, "The 340B program was created by Congress, and it's a subsidy from drug manufacturers to underserved healthcare providers. The Medicaid Drug Rebate Program is a similar program created by Congress that is a source of financial support for state Medicaid agencies, also provided by drug manufacturers. So drug manufacturers give a discount to state Medicaid agencies for drugs prescribed to Medicaid patients."
"One way to think about it is there's a lot of information asymmetry, which means some stakeholders have access to a lot more data than other stakeholders. And without a shared common understanding of which discounts are available, which discounts are compliant, and which ones aren't, it's really difficult for these various stakeholders to understand what their obligations are and what they should be doing. That leads to the dysfunction that you've mentioned."
"What Kalderos does to reduce this dysfunction is compile and curate data from dozens of different sources, to try and create a common understanding of what actually happened on a particular prescription. This is so that all stakeholders have access to the same information, which then reduces the disagreements about what should actually happen from a discount and a rebate perspective."
@KalderosInc #DrugDiscountPrograms #340BDrugDiscountProgram #MedicaidDrugRebateProgram #MDRP
